PharmiWeb1d
Analysis of The Angina Pectoris Drugs Market Growth From 2025 to 2035
Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...
Managed Healthcare Executive4d
Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025
A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...
Mirage News4d
Monoclonal Antibody Reverses Heart Attack Drug Effects
An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...
Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR
Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.
Ticagrelor antidote safely, effectively restores platelet function and treats bleeding
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...
The BMJ5d
Refining DAPT strategies after drug coated balloon angioplasty
A step forward in de-escalating treatment The evolution of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been shaped by the continuous challenge of balancing ...